Bioventus files for $150M IPO: 5 points

Spinal Tech

Bioventus has filed for an initial public stock offering, according to The News & Observer.

Here are five points:


1. The company aims to raise up to $150 million through the IPO.


2. The company intends to use the funds to "pay off promissory notes and other debt that total $60 million among other things," according to the report.


3. Bioventus, a spin-off of Smith & Nephew formed in 2012, develops orthobiologic solutions for bone fusion and osteoarthritis.


4. The company's full-year revenue increased from $242.9 million in 2014 to $253.7 million in 2015; however, its net loss in 2015 totaled $34.1 million.


5. If Bioventus moves forward with the IPO, it will trade under the ticker symbol "BIOV" on Nasdaq.


Copyright © 2023 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Podcast

Featured Whitepapers